There were 656 press releases posted in the last 24 hours and 186,068 in the last 365 days.

SIML Proscere Bioscience in Negotiations With Major Pharmaceutical Company for a $200M Deal

/EIN News/ -- Grass Valley, CA, Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) ("Simlatus" or the "Company") announces today negotiations with a major pharmaceutical company in Europe regarding a potential $200M initial order.

The company initially discussed its Hybrid Cold/Water – Alcohol based CBD Extraction system in Europe last December-2018 with a major pharmaceutical company. Negotiations are gaining ground while Proscere Bioscience is positioning itself to supply the pharmaceutical industry with CBD extraction systems to produce pharmaceutical-grade THC and CBD as a replacement for opiate based Schedule-II prescription drugs. The opioid epidemic is fueling a steep rise in infection-related stroke hospitalizations, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019. No community has been untouched by the opioid epidemic, and municipal officials are constantly confronted by the devastating losses experienced by those dealing with substance use disorder. Herculean efforts by first responders have led to widespread use of naloxone, and during the past year overdose deaths have leveled off. However, the rise of fentanyl as a heroin replacement is twisting this crisis in a deadlier direction.

The pharmaceutical industry is now developing FDA Class-III Pain Medications that are THC/CBD based and with insignificant side-effects or addiction. The best-known marijuana extract is the psychoactive compound tetrahydrocannabinol, or THC, but the plant also contains more than 60 lesser-known compounds that belong to the same chemical family as THC. There are now several major companies exploring the medicinal potential of some of these chemicals, and some of the world's largest pharma companies, including AbbVie (ABBV) and Valeant Pharmaceuticals (VRX), market products in this drug class. Proscere Bioscience will be on this radar for manufacturing the extraction processes to produce these special cannabis compounds.

Safe Harbor for Forward-Looking Statements: This news release contains forward-looking statements which are not statements of historical fact. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to changes in general economic and financial market conditions. Although the Company believes that the assumptions and  factors used in preparing the forward-looking information in this news release are reasonable,  undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed  time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.


Richard Hylen, CEO

Tel: (530) 205-3437

Primary Logo